NCT04306237View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

PHASE2SuspendedINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

April 30, 2025

Conditions
Refractory Angina
Interventions
DRUG

IMB-1018972

IMB-1018972 200 mg tablet for oral administration

DRUG

Placebo oral tablet

Matched placebo tablet for oral administration

Trial Locations (1)

02110

Imbria Investigational Site, Boston

Sponsors
All Listed Sponsors
lead

Imbria Pharmaceuticals, Inc.

INDUSTRY

NCT04306237 - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina | Biotech Hunter | Biotech Hunter